The estimated Net Worth of Sciences Ltd. Roivant is at least $168 Milione dollars as of 2 October 2023. Sciences Roivant owns over 1,526,316 units of Axovant Gene Therapies stock worth over $167,591,195 and over the last 7 years Sciences sold AXGT stock worth over $0.
Sign up
Sciences Roivant AXGT stock SEC Form 4 insiders trading
Sciences has made over 28 trades of the Axovant Gene Therapies stock since 2018, according to the Form 4 filled with the SEC. Most recently Sciences bought 1,526,316 units of AXGT stock worth $58,000,008 on 2 October 2023.
The largest trade Sciences's ever made was selling 45,008,604 units of Axovant Gene Therapies stock on 27 December 2019 worth over $94,518,068. On average, Sciences trades about 4,259,324 units every 57 days since 2017. As of 2 October 2023 Sciences still owns at least 79,805,331 units of Axovant Gene Therapies stock.
You can see the complete history of Sciences Roivant stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Sciences Roivant's mailing address?
Sciences's mailing address filed with the SEC is 7TH FLOOR, 50 BROADWAY, LONDON, X0, SW1H 0DB.
Insiders trading at Axovant Gene Therapies
Over the last 6 years, insiders at Axovant Gene Therapies have traded over $0 worth of Axovant Gene Therapies stock and bought 5,401,703 units worth $20,204,515 . The most active insiders traders include Sciences Ltd. Roivant, Andrew Lo e Associates Gp Llcqvt Financ.... On average, Axovant Gene Therapies executives and independent directors trade stock every 65 days with the average trade being worth of $1,890,596. The most recent stock trade was executed by Atul Pande on 8 July 2020, trading 10,000 units of AXGT stock currently worth $27,300.
What does Axovant Gene Therapies do?
Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.
What does Axovant Gene Therapies's logo look like?
Complete history of Sciences Roivant stock trades at Arbutus Biopharma Corp, Myovant Sciences Ltd, Urovant Sciences Ltd, Immunovant Inc e Axovant Gene Therapies
Axovant Gene Therapies executives and stock owners
Axovant Gene Therapies executives and other stock owners filed with the SEC include:
-
Pavan Cheruvu,
Chief Executive Officer, Director -
David Nassif,
Principal Financial and Accounting Officer and General Counsel, Chief Financial Officer -
Gavin Corcoran,
Chief Research and Development Officer -
Atul Pande,
Lead Independent Director -
Frank Torti,
Chairman of the Board -
Berndt Modig,
Independent Director -
Senthil Sundaram,
Independent Director -
Kristiina Vuori,
Director -
Eric Venker,
Director -
Parag Meswani,
Chief Commercial Officer -
Sciences Ltd. Roivant,
10% owner -
Investments (Uk) Ltd Soft B...,
-
George Bickerstaff,
Director -
Myrtle S Potter,
Director -
Roger Jeffs,
Director -
Associates Gp Llcqvt Financ...,
-
Mathew C. Bazley,
General Counsel -
Andrew Lo,